Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.41 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.41 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 2/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8419951 | 0.85 | BRPF1 (0.40) | ALDH1A1HPGDMAPTKDM4ETSHR | |
| SCHEMBL1505120 | 0.84 | S1PR4 (0.52) | ALDH1A1LMNAHPGDMAPTS1PR4 | |
| SCHEMBL4359950 | 0.82 | TSHR (0.53) | ALDH1A1LMNAHPGDMAPTS1PR4 | |
| SCHEMBL1505166 | 0.79 | GAA (0.60) | ALDH1A1LMNAMAPTS1PR4SGMS2 | |
| SCHEMBL11370707 | 0.79 | LMNA (0.49) | ALDH1A1LMNAHPGDMAPTS1PR4 | |
| SCHEMBL12505380 | 0.78 | LMNA (0.48) | ALDH1A1LMNAHPGDMAPTS1PR4 | |
| SCHEMBL1505088 | 0.76 | GAA (0.56) | ALDH1A1LMNAMAPTGAAKDM4E | |
| SCHEMBL19859009 | 0.72 | ABL1 (0.54) | ALDH1A1LMNAMAPTS1PR4KDM4E | |
| SCHEMBL4360418 | 0.72 | LMNA (0.51) | ALDH1A1LMNAHPGDMAPTS1PR4 | |
| SCHEMBL6421995 | 0.72 | SLC6A4 (0.51) | ALDH1A1LMNAHPGDMAPTS1PR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7618968-B2 | Aryl triazines as LPAAT-β inhibitors and uses thereof | CELL THERAPEUTICS, INC. (US) | 2009-11-17 | — | — | US | disclosed |
| US-20080064700-A1 | Aryl triazines as LPAAT-beta inhibitors and uses thereof | CELL THERAPEUTICS, INC. (US) | 2008-03-13 | — | — | US | disclosed |
| US-7291616-B2 | Aryl triazines as LPAAT-β inhibitors and uses thereof | CELL THERAPEUTICS, INC. (US) | 2007-11-06 | — | — | US | disclosed |
| US-20030153570-A1 | Aryl triazines as LPAAT-SS inhibitors and uses thereof | CELL THERAPEUTICS, INC. (US) | 2003-08-14 | — | — | US | disclosed |
| WO-2003037346-A1 | 6-PHENYL-N-PHENYL-(1,3,5) -TRIAZINE-2,4-DIAMINE DERIVATIVES AND RELATED COMPOUNDS WITH LYSOPHPHOSPHATIDIC ACID ACYLTRANSFERASE BETA (LPAAT-BETA) INHIBITORY ACTIVITY FOR USE IN THE TREATMENT OF CANCER | CELL THERAPEUTICS, INC. (US) | 2003-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030153570-A1 | Aryl triazines as LPAAT-SS inhibitors and uses thereof | LPCAT3, LPCAT1, PLAAT2 | ALDH1A1 1286/4885LMNA 2509/4885HPGD 2432/4885 |
| US-20080064700-A1 | Aryl triazines as LPAAT-beta inhibitors and uses thereof | LPCAT3, LPCAT1, PLAAT2 | ALDH1A1 827/4885LMNA 1865/4885HPGD 2426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.